Fig. 2
Association of CSF protein levels with clinical parameters of Parkinson’s disease (PD) patients. a Spearman’s rank, adjusted for age and sex, between CSF levels of significantly changed proteins in PD patients from the Stockholm cohort and disease duration, scores of Hoehn&Yahr, Unified Parkinson’s Disease Rating Scale (UPDRS) part 3, Montreal Cognitive Assessment (MoCA), Hospital Anxiety and Depression Scale (HADS), Non-Motor Symptoms Questionnaire (NMSQ) and Pittsburgh Sleep Quality Index (PSQI), and Levodopa equivalent daily dose (LEDD) (BH adjusted P-values; *P < 0.05; **P < 0.01). b Spearman’s rank, adjusted for age and sex, between CSF levels of significantly changed proteins in PD patients from the BioFIND cohort and disease duration, scores of UPDRS part 3 and MoCA, and LEDD (BH-adjusted P-values). c, d Correlation of LEDD with aromatic L-amino-acid decarboxylase levels (DDC) in the Stockholm (c) and BioFIND (d) cohorts (Spearman’s ρ, adjusted for age and sex). e Group comparisons (t-test; P-values displayed, adjusted for age and sex) between controls and PD with or without medication (PD treated and PD untreated, respectively)